



Abstract

The present invention relates to a combination of a selective PDE4 inhibitor, as defined herein, and an adrenergic $\beta 2$ receptor agonist for simultaneous, sequential or separate administration by the inhaled route in the treatment of an obstructive airways or other inflammatory disease.